Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The 'One To Three' Trial
NCT05118490Phase 4Active, not recruiting
- Sponsor
- Aurum Institute
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 4 trial of rifapentine, isoniazid in Tuberculosis (TB), sponsored by Aurum Institute. Started Jul 2023; status: active, not recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05118490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118490.